Document Detail


Mycophenolate mofetil as therapy for pyoderma gangrenosum.
MedLine Citation:
PMID:  19620559     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Pyoderma gangrenosum is an ulcerative condition that may be associated with inflammatory bowel disease or inflammatory arthritis. In addition to local wound care, management often includes the use of systemic corticosteroids or systemically administered immunomodulatory agents.
OBSERVATIONS: We retrospectively analyzed 7 patients with pyoderma gangrenosum who were treated with mycophenolate mofetil. Patients were included if they had a diagnosis of pyoderma gangrenosum and were treated with mycophenolate mofetil for at least 2 uninterrupted months. Improvement was based on reduction in lesion size or decrease in concomitant therapy. Overall, 6 of 7 patients had some reduction in ulcer size while receiving mycophenolate mofetil therapy, and 4 of 7 completely healed. However, responsiveness was inadequate in 3 patients. Two discontinued mycophenolate mofetil for alternate therapy, and the third required the addition of dapsone and infliximab for complete healing. The only adverse event observed in our analysis attributed to mycophenolate mofetil therapy was transient anemia.
CONCLUSIONS: Mycophenolate mofetil may be beneficial as an immunomodulatory agent in selected patients with pyoderma gangrenosum. Further controlled trials are warranted to define its place among the therapeutic options for this rare disease.
Authors:
Philip A Eaton; Jeffrey P Callen
Related Documents :
24589219 - The assessment of the stability in mandibular setback surgery related to spatial factor...
23738949 - Impact of gait analysis on correction of excessive hip internal rotation in ambulatory ...
3511579 - Cyclosporine as an alternative to cyclophosphamide in the treatment of chronic graft-ve...
24882459 - Recovery of vocal fold immobility following isolated patent ductus arteriosus ligation.
23314919 - Predictive risk factors of cardiorespiratory abnormality for upper gastrointestinal end...
1896809 - Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cy...
17012419 - Clinical and radiological outcome of total hip replacement five years after pamidronate...
23395119 - Treatment reduction for children and young adults with low-risk acute lymphoblastic leu...
10848939 - Occlusive dressing versus oxygen mist therapy following co2 laser resurfacing.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of dermatology     Volume:  145     ISSN:  1538-3652     ISO Abbreviation:  Arch Dermatol     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-21     Completed Date:  2009-08-06     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0372433     Medline TA:  Arch Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  781-5     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, University of Louisville, KY 40202, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Female
Humans
Immunosuppressive Agents / therapeutic use*
Male
Middle Aged
Mycophenolic Acid / analogs & derivatives*,  therapeutic use
Pyoderma Gangrenosum / drug therapy*
Retrospective Studies
Young Adult
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 24280-93-1/Mycophenolic Acid; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pictorial Representation of Illness and Self Measure (PRISM): A novel visual instrument to measure q...
Next Document:  Granuloma annulare treated with rifampin, ofloxacin, and minocycline combination therapy.